Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MC1963 Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for Patients With Advanced Stage Ovarian Cancer: A Phase II Double-Blind Randomized Clinical Trial (FAROUT)

NCT06639074 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT06639074
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06639074 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MC1963 Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for Patients With Advanced Stage Ovarian Cancer: A Phase II Double-Blind Randomized Clinical Trial (FAROUT)
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Recruiting
Start date
November 12, 2024
Completion date
April 23, 2029
Enrollment
78 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced fallopian tube carcinoma, advanced fallopian tube high grade serous adenocarcinoma, advanced ovarian carcinoma, advanced ovarian carcinosarcoma, advanced ovarian clear cell adenocarcinoma, advanced ovarian endometrioid adenocarcinoma, advanced ovarian high grade serous adenocarcinoma, advanced primary peritoneal carcinoma, advanced primary peritoneal high grade serous adenocarcinoma, fallopian tube carcinosarcoma, fallopian tube clear cell adenocarcinoma, fallopian tube endometrioid adenocarcinoma, figo stage iii ovarian cancer 2014, figo stage iv ovarian cancer 2014, ovarian mixed cell adenocarcinoma, primary peritoneal carcinosarcoma, primary peritoneal clear cell adenocarcinoma, primary peritoneal endometrioid adenocarcinoma